Nuestros investigadores

Enrique José Andreu Oltra

Líneas de investigación
DEGRADACION INTRACELULAR DE PROTEINAS EN CELULAS DE MAMIFERO, REGULACIÓN DEL CICLO CELULAR Y LA APOPTOSIS MEDIADA POR EL ONCOGEN BCR-ABL, CELULAS MADRE DEL CANCER, TERAPIA REGENERATIVA CON CELULAS MADRE ADULTAS, PRODUCCIÓN DE MEDICAMENTOS DE TERAPIA CELULAR BAJO GMP
Índice H
22, (Google Scholar, 17/05/2017)

Publicaciones científicas más recientes (desde 2010)

Autores: Mora, Gonzalo; Blanco, J. F.; et al.
Revista: JOURNAL OF TRANSLATIONAL MEDICINE
ISSN 1479-5876  Vol. 16  2018  págs. 213
Background: Mesenchymal stromal cells (MSCs) are a promising option to treat knee osteoarthritis (OA). Their safety and usefulness have been reported in several short-term clinical trials but less information is available on the long-term effects of MSC in patients with osteoarthritis. We have evaluated patients included in our previous randomized clinical trial (CMM-ART, NCT02123368) to determine their long-term clinical effect. Materials: A phase I/II multicenter randomized clinical trial with active control was conducted between 2012 and 2014. Thirty patients diagnosed with knee OA were randomly assigned to Control group, intraarticularly administered hyaluronic acid alone, or to two treatment groups, hyaluronic acid together with 10 x 10(6) or 100 x 10(6) cultured autologous bone marrow-derived MSCs (BM-MSCs), and followed up for 12 months. After a follow up of 4 years adverse effects and clinical evolution, assessed using VAS and WOMAC scorings are reported. Results: No adverse effects were reported after BM-MSCs administration or during the follow-up. BM-MSCs-administered patients improved according to VAS, median value (IQR) for Control, Low-dose and High-dose groups changed from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 7 (6, 7), 2 (2, 5) and 3 (3, 4), respectively at the end of follow up (Low-dose vs Control group, p = 0.01; High-dose vs Control group, p = 0.004). Patients receiving BM-MSCs also improved clinically according to WOMAC. Control group showed an increase median value of 4 points (-11;10) while Low-dose and High-dose groups exhibited values of -18 (-28;-9) and -10 (-21;-3) points, respectively (Low-dose vs Control group p = 0.043). No clinical differences between the BM-MSCs receiving groups were found. Conclusions: Single intraarticular injection of in vitro expanded autologous BM-MSCs is a safe and feasible procedure that results in long-term clinical and functional improvement of knee OA.
Autores: Inoges S; Tejada, Sonia; López, A; et al.
Revista: JOURNAL OF TRANSLATIONAL MEDICINE
ISSN 1479-5876  Vol. 15  Nº 1  2017  págs. 104-116
Our results suggest that the addition of tumor lysate-pulsed autologous DCs vaccination to tumor resection and combined radio-chemotherapy is feasible and safe. A multicenter randomized clinical trial is warranted to evaluate the potential survival benefit of this therapeutic approach. Trial registration This phase-II trial was registered as EudraCT: 2009-009879-35 and ClinicalTrials.gov Identifier: NCT01006044 retrospectively registered.
Autores: D'Avola, Delia; Carmona, Francisco de Asís; et al.
Revista: TRANSLATIONAL RESEARCH
ISSN 1931-5244  Vol. 188  2017  págs. 80-91.e2
The aim of this nonrandomized, open label, phase 1 clinical trial was to evaluate the safety and the feasibility of the treatment with autologous bone marrow-derived endothelial progenitor cells (EPC) in decompensated liver cirrhosis. In addition, the changes in liver function and hepatic venous pressure gradient (HVPG) and their relation with the characteristics of the cellular product were analyzed. Twelve patients with Child-Pugh ¿8 liver cirrhosis underwent bone marrow harvest for ex vivo differentiation of EPC. The final product was administered through the hepatic artery in a single administration. Patients underwent clinical and radiologic follow-up for 12 months. The phenotype and the ability to produce cytokines and growth factors of the final cellular suspension were analyzed. Eleven patients were treated (feasibility 91%). No treatment-related severe adverse events were observed as consequence of any study procedure or treatment. Model for end-stage liver disease score improved significantly (P 0.042) in the first 90 days after cells administration and 5 of the 9 patients alive at 90 days showed a decreased of HVPG. There was a direct correlation between the expression of acetylated-low density lipoprotein and von Willebrand factor in the cellular product and the improvement in liver function and HVPG. The treatment with EPCs in patients with decompensated liver cirrhosis is safe and feasible and might have therapeutic potential. Patients receiving a higher amount
Autores: Andreu, Enrique José; García, María del Rosario; et al.
Revista: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE
ISSN 0146-0404  Vol. 58  Nº 2  2017  págs. 745-754
We demonstrated that the combined activation of PI3K/Akt and Smad2 results in in vitro expansion of phenotypic and functional CEC. Expanded cells were able to contribute to restoration of corneal endothelium in a rabbit model. These findings may represent a new therapeutic approach for treating corneal endothelial diseases
Autores: Zapata, Natalia María; Mazo, Manuel María; et al.
Revista: STEM CELL RESEARCH
ISSN 1873-5061  Vol. 16  Nº 1  2016  págs. 20 - 23
In this work, mesenchymal stem cells derived from adipose tissue (ADSCs) were used for the generation of the human-induced pluripotent stem cell line G15.AO. Cell reprogramming was performed using retroviral vectors containing the Yamanaka factors, and the generated G15.AO hiPSC line showed normal karyotype, silencing of the exogenous reprogramming factors, induction of the typical pluripotency-associated markers, alkaline phosphatase enzymatic activity, and in vivo and in vitro differentiation ability to the three germ layers.
Autores: Mora, Gonzalo; Blanco JF; et al.
Revista: JOURNAL OF TRANSLATIONAL MEDICINE
ISSN 1479-5876  Vol. 14  Nº 1  2016  págs. 246
The single intraarticular injection of in vitro expanded autologous BM-MSCs together with HA is a safe and feasible procedure that results in a clinical and functional improvement of knee OA, especially when 100 × 10(6) cells are administered. These results pave the way for a future phase III clinical trial.
Autores: Baixauli, J; Núñez, Jorge María; Garcia-Olmo, D.; et al.
Revista: COLORECTAL DISEASE
ISSN 1462-8910  Vol. 18  Nº Supl. 1  2016  págs. 24
Autores: Redondo, P. ; Núñez, Jorge María; et al.
Revista: JAMA DERMATOLOGY
ISSN 2168-6068  Vol. 151  Nº 8  2015  págs. 897 - 899
Autores: Fermín Sánchez-Guijo; Teresa Caballero-Velázquez; Olga López-Villar; et al.
Revista: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
ISSN 1083-8791  Vol. 20  Nº 10  2014  págs. 1580 - 1585
We evaluated the feasibility, safety, and efficacy of the administration of 4 sequential doses (intravenously administered on days 1, 4, 11, and 18) of cryopreserved bone marrow-derived mesenchymal stromal cells (MSC) expanded with platelet lysate and obtained from third-party donors as a second-line treatment for steroid-refractory acute graft-versus-host (aGVHD) disease in a series of 25 patients. All patients received at least 2 doses of MSC, whereas 21 received 3 doses and 18 received the initially planned 4 doses. Because of the achievement of partial response, 4 patients received additional doses of MSC. Median single cell dose administered was 1.1 × 10(6) MSC/kg of recipient body weight. There were no adverse events related to the MSC infusion in the 99 procedures performed, with the exception of a cardiac ischemic event that occurred twice in a patient with prior history of cardiac ischemia. Response to MSC at 60 days after the first dose was evaluable in 24 patients. Seventeen patients (71%) responded (11 complete and 6 partial responses), with a median time to response of 28 days after the first MSC dose, whereas 7 patients did not respond. In summary, we can conclude that sequential cryopreserved third-party MSC therapy administered on days 1, 4, 11, and 18 is a safe procedure for patients with steroid-refractory aGVHD. This strategy may provide a high rate of overall responses of aGVHD with a low toxicity profile.
Autores: Guarnieri, A; Moreno, Javier; Alfonso, Belén; et al.
Revista: INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
ISSN 2222-3959  Vol. 7  Nº 6  2014  págs. 988 - 995
AIM: To assess cultured limbal epithelial stem cell transplantation in patients with limbal stem cell deficiency by analyzing and quantifying corneal neovascularization. METHODS: This retrospective, interventional case series included eight eyes with total limbal stem cell deficiency. Ex vivo limbal epithelial stem cells were cultured on human amniotic membrane using an animal-free culture method. The clinical parameters of limbal stem cell deficiency, impression cytology, and quantification of corneal neovascularization were evaluated before and after cultured limbal stem cell transplantation. The area of corneal neovascularization, vessel caliber (VC), and invasive area (IA) were analyzed before and after stem cell transplantation by image analysis software. Best-corrected visual acuity (BCVA), epithelial transparency, and impression cytology were also measured. RESULTS: One year after surgery, successful cases showed a reduction (improvement) of all three parameters of corneal neovascularization [neovascular area (NA), VC, IA], while failed cases did not. NA decreased a mean of 32.31% (P=0.035), invasion area 29.37% (P=0.018) and VC 14.29% (P=0.072). BCVA improved in all eyes (mean follow-up, 76±21mo). Epithelial transparency improved significantly from 2.00±0.93 to 0.88±1.25 (P=0.014). Impression cytology showed that three cases failed after limbal epithelial stem cell therapy before 1y of follow-up. CONCLUSION: This method of analyzing and monitoring surface vessels is useful for evaluating the epithelial status during follow-up, as successful cases showed a bigger reduction in corneal neovascularization parameters than failed cases. Using this method, successful cases could be differentiated from failed cases.
Autores: Sara Llufriu; María Sepúlveda; Yolanda Blanco; et al.
Revista: PLOS ONE
ISSN 1932-6203  Vol. 9  Nº 12  2014  págs. e113936
At baseline 9 patients were randomized to receive MSCs (n¿=¿5) or placebo (n¿=¿4). One patient on placebo withdrew after having 3 relapses in the first 5 months. We did not identify any serious adverse events. At 6 months, patients treated with MSCs had a trend to lower mean cumulative number of GEL (3.1, 95% CI¿=¿1.1-8.8 vs 12.3, 95% CI¿=¿4.4-34.5, p¿=¿0.064), and at the end of study to reduced mean GEL (-2.8±5.9 vs 3±5.4, p¿=¿0.075). No significant treatment differences were detected in the secondary endpoints. We observed a non-significant decrease of the frequency of Th1 (CD4+ IFN-¿+) cells in blood of MSCs treated patients. CONCLUSION: Bone-marrow-MSCs are safe and may reduce inflammatory MRI parameters supporting their immunomodulatory properties. ClinicalTrials.gov NCT01228266.
Autores: D'Avola, Delia; Carmona, Francisco de Asís; Mendez, M.; et al.
Revista: MOLECULAR THERAPY
ISSN 1525-0016  Vol. 22  Nº Supl.1  2014  págs. S273 - S274
Autores: D'Avola, Delia; Carmona, Francisco de Asís; Mendez, M.; et al.
Revista: HUMAN GENE THERAPY
ISSN 1043-0342  Vol. 25  Nº 11  2014  págs. A45 - A46
Autores: Iñigo Izal; Pablo Aranda; Patricia Sanz-Ramos; et al.
Revista: KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
ISSN 0942-2056  2012 
Biocompatible PLLA scaffolds have been developed that can be efficiently loaded with MSCs. The scaffold supports chondrogenic differentiation and ECM deposition that improves the mechanics of the scaffold. Although this improvement does not met the expectations of a hyaline-like cartilage ECM, in part due to the lack of a mechanical stimulation, their potential use in the treatment of cartilage pathologies encourages to improve the mechanical component.
Autores: Diez Valle, Ricardo; López, A; Inoges S; et al.
Revista: WORLD JOURNAL OF CLINICAL ONCOLOGY
ISSN 2218-4333  Vol. 3  Nº 11  2012  págs. 142-149
Active immunotherapy with tumor lysate-pulsed, autologous dendritic cells is feasible, safe, well tolerated and biologically efficacious. A phase-II study is ongoing to possibly improve further on our very encouraging clinical results.
Autores: López, Xabier; Pelacho, Beatriz; Peñuelas, Iván; et al.
Revista: CELL TRANSPLANTATION
ISSN 0963-6897  Vol. 20  Nº 2  2011  págs. 259 - 269
There is a need for comparative studies to determine which cell types are better candidates to remedy ischemia. Here, we compared human AC133(+) cells and multipotent adult progenitor cells (hMAPC) in a mouse model reminiscent of critical limb ischemia. hMAPC or hAC133(+) cell transplantation induced a significant improvement in tissue perfusion (measured by microPET) 15 days posttransplantation compared to controls. This improvement persisted for 30 days in hMAPC-treated but not in hAC133(+)-injected animals. While transplantation of hAC133(+) cells promoted capillary growth, hMAPC transplantation also induced collateral expansion, decreased muscle necrosis/fibrosis, and improved muscle regeneration. Incorporation of differentiated MC 133(+) or hMAPC progeny into new vessels was limited; however, a paracrine angio/arteriogenic effect was demonstrated in animals treated with hMAPC. Accordingly, hMAPC-conditioned, but not hAC133(+)-conditioned, media stimulated vascular cell proliferation and prevented myoblast, endothelial, and smooth muscle cell apoptosis in vitro. Our study suggests that although hAC133(+) cell and hMAPC transplantation both contribute to vascular regeneration in ischemic limbs, hMAPC exert a more robust effect through trophic mechanisms, which translated into collateral and muscle fiber regeneration. This, in turn, conferred tissue protection and regeneration with longer term functional improvement.
Autores: Redondo, P. ; Giménez de Azcárate Trívez, A.; Marqués Martín, L.; et al.
Revista: Dermatology Research and Practice
ISSN 1687-6105  Vol. Article ID 532139, 6 pages  2011  págs. 532139-
Patients were followed for up to 6 months using clinical assessment of achromic lesions. Treated areas ranged between 4¿cm(2) and 210.6¿cm(2). Response to treatment was excellent in all patients with 90-95% repigmentation success rate.
Autores: Peña, E.; Andreu, Enrique José; Pérez-Ilzarbe, M.; et al.
Revista: JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
ISSN 1549-3296  Vol. 96  Nº 2  2011  págs. 341 - 348
A better cell adhesion rate was observed in the cross-linked meshes. An increase in the mechanical properties after cell seeding was observed with a direct relation with the degree of cross-linking. All meshes analyzed showed a marked anisotropy that should be taken into account during the surgical procedure. The cross-linking treatment increased cell adhesion and the mechanical properties of the collagen meshes after seeding. These results suggest that the mechanical properties of this type of collagen mesh could be useful as scaffolds for repair of pelvic organ prolapse.
Autores: Pérez-Simón, JA.; López Villar, Olga; Andreu, Enrique José; et al.
Revista: HAEMATOLOGICA
ISSN 1138-0381  Vol. 96  Nº 7  2011  págs. 1072-1076
This trial evaluated the feasibility and efficacy of the infusion of mesenchymal stem cells expanded using human serum for the treatment of refractory acute or chronic graft-versus-host disease. Twenty-eight expansions were started. In 22, a minimum of more than 1x106 mesenchymal stem cells/kg were obtained after a median of 26 days; this threshold was not obtained in the remaining cases. Ten patients received cells for the treatment of refractory or relapsed acute graft-versus-host disease and 8 for chronic disease. One patient treated for acute graft-versus-host disease obtained a complete response, 6 had a partial response and 3 did not respond. One of the chronic patients achieved complete remision, 3 a partial response, and 4 did not respond. The current study supports the use of this approach in less heavily treated patients for both acute and chronic graft-versus-host disease.
Autores: Albero, MP; Vaquer, JM; Andreu, Enrique José; et al.
Revista: Oncogene
ISSN 0950-9232  Vol. 29  Nº 22  2010  págs. 3276 - 3286